NCHR Testimony at the FDA about New Spine Device, Barricaid Anular Closure

Thank you for the opportunity to speak today on behalf of the National Center for Health Research. I am Dr. Danielle Shapiro, I am a physician and senior fellow. Our research center scrutinizes scientific and medical data and provides objective health information to patients, providers and policy makers. Those are the perspectives I bring with me today. […]

Read More »

NCHR testimony at FDA about Clinical Trial Criteria for Interstitial Cystitis and Bladder Pain Syndrome

December 7, 2017. There is a need for new treatment options for interstitial cystitis and bladder pain syndrome (IC/BPS). These conditions have a range of causes and symptoms, and symptoms can be very similar to other conditions. This variation adds complexity to testing new treatments.  To meet the needs of patients, the FDA must hold the sponsors’ clinical trials to a high standard that ensures safe and effective treatments.

Read More »

NCHR Comments to HHS on Religious Exemptions and Contraceptives

December 5, 2017. We strongly oppose the IFR’s use of religious objections to undermine essential health care for millions of women in our country. The HHS must ensure the health of all our citizens by implementing policies based on sound medical and public health science. We urge that HHS bring evidenced-based practice into the forefront of health policies, as it has for decades.

Read More »

NCHR Comments on the USPSTF Draft Recommendations for Osteoporosis Screening

December 5, 2017. We strongly suggest the USPSTF provide a separate and clear “D” recommendation against screening in premenopausal women younger than 65. We strongly recommend that the USPSTF not finalize its recommendations until further information is made available regarding the direct benefits and harms of screening as noted above. In addition, we strongly urge that the evidence supports that the harms of drug therapies are “moderate” or “moderate to severe” and these risks be compared to the lack of evidence that these drugs reduce hip fractures, rather than concluding that the benefits are substantial and the risks are “no greater than small.” Last, we urge that USPSTF examine the benefits and harms of non-drug therapies as part of its screening recommendations.

Read More »
Page 1 of 8912345...102030...Last »